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This randomised multicentre trial was conducted to establish the optimal duration of palliative chemotherapy in advanced non-small-
cell lung cancer (NSCLC). We compared a policy of three vs six courses of new-generation platinum-based combination
chemotherapy with regard to effects on quality of life (QoL) and survival. Patients with stage IIIB or IV NSCLC and WHO
performance status (PS) 0–2 were randomised to receive three (C3) or six (C6) courses of carboplatin (area under the curve
(AUC) 4, Chatelut’s formula, equivalent to Calvert’s AUC 5) on day 1 and vinorelbine 25mgm
 2 on days 1 and 8 of a 3-week cycle.
Key end points were QoL at 18 weeks, measured with EORTC Quality of Life Questionnaire (QLQ)-C30 and QLQ-LC13, and
overall survival. Secondary end points were progression-free survival and need of palliative radiotherapy. Two hundred and ninety-
seven patients were randomised (C3 150, C6 147). Their median age was 65 years, 30% had PS 2 and 76% stage IV disease. Seventy-
eight and 54% of C3 and C6 patients, respectively, completed all scheduled chemotherapy courses. Compliance with QoL
questionnaires was 88%. There were no significant group differences in global QoL, pain or fatigue up to 26 weeks. The dyspnoea
palliation rate was lower in the C3 arm at 18 and 26 weeks (Po0.05), but this finding was inconsistent across different methods of
analysis. Median survival in the C3 group was 28 vs 32 weeks in the C6 group (P¼0.75, HR 1.04, 95% CI 0.82–1.31). One- and 2-
year survival rates were 25 and 9% vs 25 and 5% in the C3 and C6 arm, respectively. Median progression-free survival was 16 and 21
weeks in the C3 and C6 groups, respectively (P¼0.21, HR 0.86, 95% CI 0.68–1.08). In conclusion, palliative chemotherapy with
carboplatin and vinorelbine beyond three courses conveys no survival or consistent QoL benefits in advanced NSCLC.
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During the last decade, chemotherapy has become widely used in
the palliative treatment of patients with advanced non-small-cell
lung cancer (NSCLC). Today, it is acknowledged that platinum-
based chemotherapy improves quality of life (QoL) (Helsing et al,
1998; Cullen et al, 1999; Gridelli et al, 1999; Thongprasert et al,
1999; Anderson et al, 2000; Ranson et al, 2000) and increases
survival in patients with a good performance status (PS) by 2–3
months (Marino et al, 1994; Anonymus, 1995; Souquet et al, 1995;
Spiro et al, 2004). Two-drug platinum-based regimens have proven
superior to single drug therapy and equivalent in efficacy to three-
drug regimens (Alberola et al, 2003; Delbaldo et al, 2004). Given
potential side effects, time spent in hospital, the cost of patient
care, interindividual response variation and the palliative nature of
the chemotherapy, it is clinically highly relevant to establish the
optimal treatment duration. Evidence concerning this question
is scarce. Two trials of induction vs induction plus maintenance
treatment in responding patients with advanced NSCLC suggested
that treatment could be confined to two or three cycles (Buccheri
et al, 1989; Weynants et al, 1997), but none of these trials
specifically addressed the question of treatment duration. An
expert panel at the American Society of Clinical Oncology in 1997
(Anonymus, 1997) recommended a maximum of eight chemother-
apy courses in patients with stage IV NSCLC. The 2003 update of
Received 29 March 2006; revised 14 August 2006; accepted 14 August
2006
*Correspondence: Dr C von Plessen;
E-mail: christian.von.plessen@helse-bergen.no
8For the Swedish Lung Cancer Study Group
9Current address: Fromreide Legesenter, Kjerrgarden, Norway
10Current address: Department of Pulmonary Medicine, Linko ¨ping
University Hospital and University of Linko ¨ping, Linko ¨ping, Sweden
British Journal of Cancer (2006) 95, 966–973
& 2006 Cancer Research UK All rights reserved 0007– 0920/06 $30.00
www.bjcancer.com
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sthe guidelines recommended limiting chemotherapy to six cycles
in general and stopping treatment after four cycles in stage IV
patients who do not respond to treatment. These recommenda-
tions were based on a trial comparing three vs six courses of
mitomycin, vinblastine and cisplatin (Smith et al, 2001), and a
study that compared four courses of carboplatin/paclitaxel with
the same combination given until progression (Socinski et al,
2002). Neither trial showed benefits from longer treatment
duration.
The current trial was designed to compare a treatment policy of
three (C3) vs six (C6) cycles of a modern platinum-based two-drug
combination regimen. The main research question was whether six
courses would be superior to three courses with respect to QoL and
survival outcomes.
MATERIALS AND METHODS
Patients
Patients with cytologically or histologically verified NSCLC stage
IIIB or IV who were not candidates for treatment with a curative
intent and who had a WHO PS of 0, 1 or 2 were eligible. No upper
age limit was defined. A white blood cell (WBC) count
43.0 10
9l
 1, platelet count 4100 10
9l
 1, serum creatinine
o1.5 times the upper reference limit, and bilirubin, ASAT and
ALAT less than twice the upper reference limit were required.
Exclusion criteria were other active malignancy, pregnancy or
breast feeding. Patients had to be chemotherapy naı ¨ve and had to
understand oral and written information.
Baseline investigations
Demographic and clinical data (age, gender, histological or
cytological tumour type, PS, disease stage, body height and
weight) as well as laboratory measures (haemoglobin, leucocyte
and platelet counts, sodium, potassium, calcium, albumin, ASAT,
ALAT, bilirubin, alkaline phosphatase, lactate dehydrogenase and
creatinine) were recorded. All patients had to complete the first
QoL questionnaire before randomisation.
Chemotherapy
Patients were randomised to receive three (C3) or six (C6) courses
of intravenous (i.v.) carboplatin and vinorelbine. Both drugs were
administered on day 1, generally on an outpatient basis, and
vinorelbine was repeated on day 8 of each 3-week cycle.
Haematologic parameters were measured before each chemother-
apy administration and on day 15. The dose of carboplatin was
calculated by means of Chatelut’s formula (area under the curve
(AUC)¼4), and the vinorelbine dose was 25mgm
 2. Vinorelbine,
diluted in 100ml glucose 50mgml
 1, was given as a 10min
infusion, and carboplatin, diluted in 500ml glucose 50mgml
 1,
was infused during 1h. Area under the curve¼4 in Chatelut’s
formula corresponds to AUC¼5 in Calvert’s. Immediately before
chemotherapy on day 1, patients received antiemetic prophylaxis
with dexamethasone or betametasone 8mg i.v. and ondansentron
8mg (alternatively tropisetron 5mg) i.v. Antiemetic prophylaxis
on day 8 was optional.
In case of moderate haematological toxicity (WBC 2.5–
2.9 10
9l
 1 and/or platelets 75–99 10
9l
 1) on day 1 of
subsequent treatment courses, the doses of carboplatin and
vinorelbin were reduced by 33%. In case of more pronounced
haematological toxicity (WBC o2.5 10
9l
 1 and/or platelets
o75 10
9l
 1), the next chemotherapy course was postponed for
1 week and all subsequent courses remained reduced by 33%. In
patients with leukopenia-associated infection chemotherapy was
postponed until clinical recovery and normalised WBC and
platelets. At continuation, further doses were reduced by 33%.
Treatment was prematurely discontinued in case of disease
progression, unacceptable toxicity, or on the patient’s request.
Randomisation
First patients signed the informed consent form and completed the
baseline QoL questionnaire. Then they were randomised after
stratification by PS (0–1 vs 2) and by institution using a
minimisation process with a probability of 0.75 (Pocock, 1985).
Assessment of QoL
Quality of life was measured by the patient-completed EORTC
Core Quality of Life Questionnaire (QLQ-C30 version 2) (Aaronson
et al, 1993) and the lung cancer-specific module QLQ-LC13
(Bergman et al, 1994). The QLQ-C30 measures functional aspects
of QoL and symptoms commonly reported in cancer patients,
while the QLQ-LC13 addresses symptoms specifically associated
with lung cancer and its treatment. In the present trial, dyspnoea,
pain, fatigue and global QoL were predefined as the primary QoL
outcome measures. Quality of life assessments were scheduled at
baseline and then at weeks 3, 6, 9 (end of C3 study treatment), 12,
15, 18 (end of C6 study treatment), 26, 34, 42 and 50 in both study
arms. In this study, QoL questionnaires up to 26 weeks were used
for analysis. Follow-up questionnaires were either administered at
the scheduled outpatient visits (Sweden) or mailed directly from
the study office to the patients (Norway). Patients received one
mailed reminder after 14 days if the questionnaire was not
returned.
Assessment of toxicity
At the first visit in each treatment cycle and at the 8-weekly follow-
up visits, patients underwent clinical examination with an
evaluation of PS, weight and blood tests. Local investigators
recorded nadir values of haemoglobin, leucocyte and platelet
counts, the number of transfusions, leukopenic infections,
thrombocytopenic bleedings, events of phlebitis during the study
treatment period and hospital admissions due to chemotherapy
side effects. After a patient’s death or at registration cutoff in June
2004, investigators also reported additional treatments such as
radiation, second-line chemotherapy or surgery as well as the
cause of death. Mortality data were verified by the national
mortality registries.
Assessment of disease progression
Tumour status was evaluated by using chest X-ray, performed in
both treatment arms at baseline, after completion of the scheduled
courses, and then every eighth week or at the investigators’
discretion. Disease progression was defined either as an increase of
the longest measurable tumour diameter by at least 20% compared
to the minimum length after treatment start, or by the occurrence
of new metastases, or death with residual tumour.
Study end points
Main end points of the study were QoL at 18 weeks and overall
survival. Further end points were progression-free survival and
need of palliative radiotherapy.
Statistical considerations
Sample size was estimated to detect a mean global QoL difference
at 18 weeks of 11 score points or more on the QLQ-LC30 scale
ranging from 0 to 100, which is considered a clinically significant
score difference (King, 1996; Osoba et al, 1998). With an s.d. of 23
(Aaronson et al, 1993), a type I error of 5% and power of 80%
Duration of palliative chemotherapy for NSCLC
C von Plessen et al
967
British Journal of Cancer (2006) 95(8), 966–973 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
susing a two-sided t-test, these criteria required 70 evaluable
patients in each group. Assuming a drop-out rate by 18 weeks of
about 50% due to disease progression or death, 300 randomised
patients were considered necessary.
With respect to chemotherapy-related haematological side
effects, the maximum toxicity ever experienced during treatment
is reported. Differences between treatment arms were tested with a
w
2 test. Survival time was measured from the date of randomisa-
tion. Survival curves were calculated by the method of Kaplan and
Meier and compared by the log-rank test. Additionally, a Cox
model was used for estimation of hazard ratios. All data analyses
followed the intention-to-treat principle.
Quality of life outcomes were analysed in four ways: (1)
group comparison of scale scores at each time point, (2) score
changes from baseline, (3) AUC and (4) rates of symptom
palliation defined as improvement, control or prevention,
and death counted as nonpalliation (Stephens et al, 1999).
Improvement was defined as a change in reported baseline
symptom levels from moderate or severe (67–100 points) to
none or little (0–33 points) (Langendijk et al, 2000), or from little
to no symptoms without subsequent deterioration by the time of
group comparison. Control of symptoms was defined as stable
symptom levels between 1 and 33 points, while prevention of
symptoms was assumed when patients did not report symptoms
during the study period. A similar approach was used for the
global QoL scale. Here, four score level ranges were defined: 0–24,
25–49, 50–74 and 75–100, with 0 being the worst and 100 the best
possible score.
Main time point for the analysis of the QoL outcome was at 18
weeks, and assessment at 26 weeks was considered important for
confirmatory analyses. Assessment at 9 weeks served as quality
control of treatment arm balance. Nonparametric tests were used
for group comparisons. Group differences that were consistent
across methods of analysis or detected with a P-value of 0.01 or
less were interpreted as probable treatment effects.
Ethical considerations
The study protocol was approved by the Regional Ethical
Committee of Western Norway and at the University of Gothen-
burg, Sweden.
RESULTS
Patient characteristics
From May 2000 until March 2002, 300 patients were randomised at
five university hospitals and 20 regional and local hospitals in
Norway (24 centres, N¼262) and Sweden (one centre, N¼38).
Three patients with thyroid, small-cell lung and peritoneal cancer,
respectively, were misdiagnosed and excluded from the study,
leaving 297 patients (C3 150, C6 147). Median follow-up time by
June 2004 was 36 months. Patients’ pretreatment characteristics
are presented in Table 1. The treatment arms were well balanced
with regard to age, PS, stage and histology, while the C6 arm
comprised a larger proportion of females.
Compliance with chemotherapy
Completion of all planned chemotherapy courses was reported
in 117 (78%) and 79 (54%) patients in the C3 and C6 arm,
respectively (Table 2). The mean and corresponding median
numbers of courses were 2.7 and 3, respectively, in the C3 arm and
4.5 and 6, respectively, in the C6 arm. Vinorelbine on day 8 was
omitted at least once in five patients in the C3 arm and in 20
patients in the C6 group.
Compliance with QoL questionnaires
Two hundred and ninety-seven patients returned 1715 completed
questionnaires (of 1911 expected, deceased patients excluded)
during the initial 26 weeks study period. Thirty questionnaires
were not adequately filled in, leaving 1685 evaluable questionnaires
(C3, N¼826; C6, N¼859). Thus, the compliance rate with QoL
questionnaires during the study period was 88% (C3 86%; C6
91%).
QoL outcome
Scores for global QoL as well as dyspnoea, pain and fatigue at
baseline, 9, 18 and 26 weeks are displayed in Table 3.
C6 patients reported lower dyspnoea scores, as measured by the
three-item QLQ-LC13 dyspnoea scale, at 18 and 26 weeks than did
the C3 patients. These group differences were not seen with the
single-item QLQ-C30 dyspnoea measure. No significant group
differences were seen at any time point for pain, fatigue or global
QoL.
Mean score changes from baseline to 9, 18 and 26 weeks are
shown in Figure 1.
The changes of dyspnoea scores suggested a small symptom
increase over time in both treatment groups, with no significant
group differences at 18 or 26 weeks. Changes of pain scores did not
differ up to 18 weeks, whereas a trend towards a less favourable
outcome in the C6 group at 26 weeks was detected (P¼0.08).
Table 1 Patient characteristics at baseline
Treatment group
C3 C6 Total
No. of patients 150 147 297
Sex, M/F 104/46 84/63 188/109
Age, median (range) 64 (35–84) 65 (34–83) 64 (34–84)
PS
03 1 2 6 5 7
1 76 74 150
24 3 4 7 9 0
Stage
IIIB 37 34 71
IV 113 113 226
Histology
Adenocarcinoma 63 66 129
Squamous cell 46 33 79
Large cell 15 21 36
Adenosquamous 3 0 3
NSCLC – not specified 23 27 50
NSCLC¼non-small-cell lung cancer; PS¼performance status.
Table 2 Numbers and percentages of patients treated at each course
Course number
123 4 5 6
C3 (N¼150) 150 136 117 — — —
Per cent 100 91 78 — — —
C6 (N¼147) 143 134 116 99 88 79
Per cent 97 91 79 67 60 54
C3 patients were randomised to receive three courses, while C6 patients were
randomised to receive six courses of chemotherapy
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sSimilarly, fatigue scores tended to increase somewhat more in the
C6 group at 18 (P¼0.13) and 26 weeks (P¼0.09). Global QoL
tended to deteriorate over time in both C3 and C6 patients.
However, score changes did not differ significantly between the
groups.
Analysis of AUC up to 18 and 26 weeks did not reveal any
significant group differences in any of the core symptom items or
global QoL (data not shown).
Finally, palliation rates of the core symptoms and global QoL are
displayed in Figure 2.
Palliation rates varied from 34% (fatigue) to 55% (global QoL)
by 9 weeks (C3 and C6 combined), but declined over time. A
significantly larger proportion of C6 than C3 patients were still
palliated with regard to dyspnoea at 18 (Po0.05) and 26
(Po0.001) weeks when measured by the three-item QLQ-LC13
dyspnoea scale, but this group difference could not be detected
with the single-item QLQ-C30 dyspnoea measure. As for the
fatigue measure, there seemed to be a palliation advantage for the
C6 group at 9 weeks (Po0.05), which could hardly be attributable
to treatment effects. By the 18 and 26 weeks follow-up measure-
ments, there were no significant group differences in palliation of
fatigue, pain or global QoL.
With regard to the remaining QoL measures, which were used
for exploratory purposes, there was a larger deterioration in role
functioning scores from baseline to 26 weeks in the C6 group
(mean score change  19.0 vs  7.4 in the C3 group, Po0.05) and
increased nausea and vomiting by 18 weeks (mean score change
þ4.2 vs  0.4 in the C3 group, Po0.05). In the C3 group, there was
Table 3 Mean scores for the primary QoL outcome dimensions at 0, 9, 18 and 26 weeks by treatment group
0 weeks 9 weeks 18 weeks 26 weeks
C3 C6 C3 C6 C3 C6 C3 C6
No. of patients alive 150 147 129 127 96 99 75 80
No. of questionnaires 148 147 105 108 78 87 63 73
Global QoL 50.8 56.7 54.1 58.4 49.6 55.3 49.0 52.4
Dyspnoea (QLQ-C30) 49.0 48.3 46.1 41.7 53.0 47.7 54.5 46.6
Dyspnoea (QLQ-LC13) 37.9 37.8 38.6 35.0 45.1 37.6
* 47.9 38.3
*
Pain 35.7 30.6 30.6 27.8 29.5 30.7 34.7 38.8
Fatigue 47.2 44.5 49.8 47.1 49.4 50.2 52.1 51.1
QLQ¼Quality of Life Questionnaire; QoL¼quality of life. All scale scores range from 0 to 100. For Global QoL, a higher score indicates better QoL, while for the symptom
measures, a higher score indicates more pronounced symptoms. *Po0.05; Mann–Whitney U-test.
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Figure 1 Mean score changes from baseline to key follow-up time points for primary outcome symptoms and global QoL, calculated from individual
patients measured at baseline and 9 weeks (C3, N¼105; C6, N¼103), 18 weeks (C3, N¼77; C6, N¼87) and 26 weeks (C3, N¼62; C6, N¼73),
respectively. For symptom measures score, changes 40 indicate increased symptoms (i.e. deterioration), while for the global QoL score, changes 40
indicate improvement. No significant group differences were seen.
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sa larger improvement in the arm/shoulder pain score by 18 weeks
(mean score change  10 vs  0.8 in the C6 group, Po0.05).
Otherwise, there were no significant group differences in score
levels, score changes, AUC or palliation rates up to 26 weeks.
Survival
Overall survival is shown in Figure 3. Median survival time was 28
and 32 weeks in the C3 and C6 arm, respectively (P¼0.75). The
hazard ratio for the C6 arm was 1.04 (95% CI 0.82–1.31). One- and
2-year survival rates were 25 and 9% vs 25 and 5% in the C3 and C6
arm, respectively.
By June 2004, 288 patients were dead. The cause of death was
recorded in 275 patients, 254 deaths were related to lung cancer,
two to chemotherapy side effects and three were related to side
effects of other cancer treatments. Sixteen patients died of other
causes than lung cancer or its treatment.
Progression-free survival time is shown in Figure 4. Median
progression-free survival time was 16 and 21 weeks in the C3 and
C6 groups, respectively (P¼0.21). The hazard ratio for the C6 arm
was 0.86 (95% CI 0.68–1.08).
Additional treatment after completed chemotherapy
A total of 285 patients were assessable for additional treatments
after completed first-line chemotherapy. Of these patients, 62
(22%) in the C3 arm and 68 (24%) in the C6 arm received palliative
irradiation (P¼0.4). Overall, sixty-four patients received second-
line chemotherapy, 35 (12%) in the C3 group and 29 (10%) the C6
group (P¼0.4).
Toxicity
Haematological toxicities are presented in Table 4. Approximately
one-third of patients in both treatment groups experienced grade 3
or 4 leukopenia.
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*
Figure 2 Rates of palliation of core symptoms and global QoL, defined as improvement, control or prevention, and death counted as nonpalliation.
Numbers of evaluable patients (including deceased) were 256 at 9 weeks (C3 127, C6 129), 270 at 18 weeks (C3 133, C6 137) and 282 at 26 weeks (C3
140, C6 142). *Po0.05; ***Po0.001; w
2 test.
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Figure 3 Overall survival by treatment group: C3 (randomised to
receive three courses) marked with solid line and C6 (randomised to
receive six courses) with dotted line. P-value refers to a log-rank test.
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sOther side effects were evaluable in 87% of all patients. In the C3
group, 27 (20%) patients had leukopenic infections compared with
21 (16%) in the C6 group (P¼0.5). The total number of blood
transfusions was 20 (15%) in the C3 vs 44 (34%) in the C6 group
(P¼0.003). No thrombocytopenic bleedings were recorded. There
was one episode of grade 5 toxicity in each treatment arm.
Fourteen (11%) vs 18 (14%) in the C3 and C6 group, respectively,
had episodes of phlebitis (P¼0.5). Thirty-two (C3) and 26 (C6)
hospital admissions due to chemotherapy side effects were
recorded (P¼0.3).
DISCUSSION
In this randomised multicentre trial in two Scandinavian countries
a treatment policy of six courses of a platinum-based two-drug
chemotherapy regimen did not convey any survival or consistent
QoL benefits over three courses of the same regimen, with
comparable toxicity. These findings challenge recent guidelines
that recommend a maximum of six courses of chemotherapy in
stage IV NSCLC (Pfister et al, 2004).
In this study, group differences in QoL measures were generally
small and inconsistent across methods of analysis. The QoL
results did not indicate improved pain or fatigue control with the
C6 regimen. Neither did patients’ functioning or global QoL
significantly improve with the longer treatment. On the other
hand, the perceived side effects of prolonged treatment were
marginal, mainly consisting of moderately increased nausea and
vomiting. The only variable that pointed to a potential benefit from
prolonged treatment was improved dyspnoea control at 18 and 26
weeks in the C6 vs C3 arm when measured by the three-item QLQ-
LC13 scale. However, no corresponding difference in dyspnoea
control was shown in score changes from baseline or AUC
comparison, neither was it reproduced with the single-item QLQ-
C30 dyspnoea measure. The latter could possibly be explained by
an increased sensitivity to clinical change with the three-item scale
(Bergman et al, 1994).
The study is representative of the everyday clinical setting with
over 20% of all newly diagnosed stage IIIB and IV NSCLC patients
in the Norwegian study regions (Cancer Registry of Norway, 2005)
participating. Of these patients, 45% were over the age of 65 years
compared to 61% in the Norwegian Cancer Registry. Still, the
proportion of elderly patients was higher than in typical clinical
lung cancer trials (Hutchins et al, 1999; Lewis et al, 2003; Murthy
et al, 2004).
At the time this study was planned, single-drug efficacy of
vinorelbine had been demonstrated (Gridelli et al, 1997) and the
combination of carboplatin and vinorelbine was well tolerated
in phase II trials (Masotti et al, 1995; Pronzato et al, 1996; Gridelli
et al, 1998, 1999; Santomaggio et al, 1998). Later vinorelbine/
cisplatin regimens have shown similar efficacy when compared to
other cisplatin combinations with third-generation cytotoxic drugs
(Schiller et al, 2002). A recent meta-analysis comparing cisplatin
and carboplatin in the treatment of advanced NSCLC found
no significant differences in overall survival in spite of a higher
response rate for cisplatin. Treatment with cisplatin was associated
with more nausea–vomiting than carboplatin (Ardizzoni et al,
2006). For the palliative treatment in the unselected population of
this study, we assumed equal efficacy of both drugs and chose
carboplatin because of its more feasible outpatient administration
and more favourable toxicity profile.
The proportion of patients receiving second-line chemotherapy
(C3 12%, C6 10%) was small in comparison to a recent survey
(Hensing et al, 2005) that reported 45% second-line chemotherapy
for the patient population of an earlier phase III trial (Socinski
et al, 2002). However, these figures are representative of the
pattern of chemotherapy use for NSCLC in Norway when the study
was initiated in 2000. In fact, the study was instrumental in
introducing chemotherapy for advanced NSCLC in the country.
A consequence of the relatively infrequent use of second-line
treatment is that the analysis of overall survival by first-line
treatment strategies is less biased.
The evaluation of progression-free survival and chemotherapy
toxicity reported by the local investigators was not systematically
reviewed and the information on validity of these data is limited.
However, the main study end points, overall survival and QoL,
were recorded independently of local investigators, and were
therefore not affected by this limitation.
During the inclusion phase of the present study, a British group
(Smith et al, 2001) reported the results from a randomised trial of
three vs six courses of mitomycin, vinblastine and cisplatin in 308
patients with NSCLC, stage IIIB and IV, and PS 0–2. They found
similar median survival times and 1-year survival rates for patients
in both study arms, indicating no survival benefit from the longer
duration of chemotherapy. Furthermore, QoL and duration of
symptom relief were similar in both arms, although patients
receiving six courses reported somewhat more pronounced fatigue,
nausea and vomiting, probably related to increased treatment
toxicity. The two studies were comparable in terms of design and
study population, but ours had a higher median age of 65 vs 63
years in the British study. Furthermore, treatment compliance was
higher in this study, with 78 and 54% completion rate in the C3
and C6 arm, respectively, compared with 72 and 31% in the British
trial. This difference probably reflects a better tolerance for the
vinorelbine/carboplatin regimen.
In 2002, Socinski et al (2002) reported the results from a
randomised study comparing four courses of carboplatin/
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Figure 4 Progression-free survival by treatment group: C3 (randomised
to receive three courses) marked with solid line and C6 (randomised to
receive six courses) with dotted line. P-value refers to a log-rank test.
Table 4 Numbers (%) of patients in each treatment arm experiencing
haematological toxicity by worst CTC grading
C3 (N¼150) C6 (N¼147)
CTC grade 1+2 3+4 1+2 3+4 P-value
WBC 54 (36) 52 (35) 57 (40) 46 (32) 0.79
Haemoglobin 133 (89) 5 (3) 121 (85) 13 (9) 0.11
Platelets 30 (20) 2 (1) 50 (35) 1 (1) 0.02
CTC¼common toxicity criteria; WBC¼white blood cell. P-values refer to w
2 tests.
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spaclitaxel chemotherapy with continuous treatment until progres-
sion in 230 patients with NSCLC stage IIIB or IV and PS 0–1. In
both arms, the median number of actually delivered chemotherapy
courses was 4, with 57% of patients in the short treatment arm
receiving all scheduled treatments, and 42% of patients in the
continuous treatment arm receiving five or more courses. In spite
of their generally more fit study population (no PS 2 patients),
prolonged treatment did not yield any benefits in terms of survival,
QoL or response rates. An increasing rate of peripheral neuropathy
was seen in patients receiving more than four courses.
Limiting the number of chemotherapy courses would reduce
total treatment costs (Braud et al, 2003) as cytotoxic drugs and
their administration constitute 14–20% (Jaakkimainen et al, 1990;
Billingham et al, 2002) of the health-care costs of advanced lung
cancer. Furthermore, as many patients spend hours in hospital
(Plessen von and Aslaksen, 2005) and travelling back and forth for
chemotherapy, a reduction in the number of courses will also
directly benefit the patient. Finally, reducing the number of
courses can free limited oncological outpatient capacity (Clegg
et al, 2001).
Around 50% of patients with lung cancer receive chemotherapy
during more than 2 months of the final 6 months of their lives, and
10% during their last 4 weeks (Emanuel et al, 2003). These
proportions are considerable taking into account limited benefits
(Spiro and Porter, 2002) and toxicity of chemotherapy. Further-
more, it cannot be expected that patients, after completed
treatment, generally have a positive attitude towards chemother-
apy (Silvestri et al, 1998). On the other hand, it has been shown
that patients with cancer are willing to accept toxic therapy for
minimal benefits (Slevin et al, 1990; Bremnes et al, 1995; Hirose
et al, 2005). It is a challenge for any clinician to give balanced
information about potential effects and side effects of palliative
chemotherapy and when to stop the treatment (Mitchell and
Currow, 2002). The confirmatory evidence from this study,
indicating similar QoL and survival after three or six courses of
chemotherapy, will hopefully support clinicians and their patients
in the decision-making process regarding the duration of palliative
chemotherapy, and should be taken into account in clinical
guidelines on the palliative treatment of advanced NSCLC.
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